<p>Axitinib has been shown to inhibit receptor&nbsp;tyrosine&nbsp;kinases including&nbsp;vascular endothelial growth factor&nbsp;receptors (VEGFR)-1, VEGFR-2, and VEGFR-3 at therapeutic plasma concentrations. These receptors are implicated in&nbsp;pathologic&nbsp;angiogenesis, tumor growth, and cancer progression.&nbsp;VEGF-mediated&nbsp;endothelial&nbsp;cell proliferation and survival were inhibited by axitinib&nbsp;in vitro&nbsp;and in mouse models. Axitinib was shown to inhibit tumor growth and&nbsp;phosphorylation&nbsp;of VEGFR-2 in tumor&nbsp;xenograft&nbsp;mouse models.</p>